Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Follow-Up Treatment GOAL Trial B-cell Lymphoma NCT02499003

- 01/01/2018 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue

Groupes Item: Admininstrative data, Follow-Up Lymphoma Treatment

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Study part: Follow-Up Lymphoma Treatment. Visit: All visits. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Long-Term Follow-Up for Survival and Disease Status

- 07/04/2021 - 1 Formulaire, 9 Groupes Item, 29 Eléments de données, 1 Langue

Groupes Item: Administrative, Long-Term Follow-Up for Survival and Disease Status, Since the time the last LTFU was completed, has any of the following occured?, Subsequent NHL Therapy since last LTFU, Myelodysplasia, Another malignancy, Thyroid medication, HAMA, Investigator Signature

Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Long-Term Follow-Up for Survival and Disease Status; Patient Withdrawal from Study; Notification of Patient Death; Clarification Form

- 01/04/2021 - 1 Formulaire, 5 Groupes Item, 34 Eléments de données, 1 Langue

Groupes Item: Administrative, Long-Term Follow-Up for Survival and Disease Status, Patient Withdrawal from Study, Notification of Patient Death, Clarification Form

Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma NCT00992758 - Follow-Up - Physical Examination; Laboratory Results; Post-Treatment Response

- 01/04/2021 - 1 Formulaire, 16 Groupes Item, 59 Eléments de données, 1 Langue

Groupes Item: Administrative, Physical Examination (Follow-Up), Physical Examination (Follow-Up), Laboratory Results - Hematology/ Chemistry (Follow-Up), Laboratory Results (Follow-Up) - Hematology, Laboratory Results (Follow-Up) - Hematology, Laboratory Results (Follow-Up) - Chemistry, Laboratory Results (Follow-Up) - Chemistry, Post-Treatment Response (Follow -Up), Post-Treatment Response (Follow-Up) - CT or other Radiological Imaging Results, Post-Treatment Response (Follow-Up) - Bone Marrow Biopsy, Post-Treatment Response (Follow-Up) - Measurable Lymphoma Disease, Post-Treatment Response (Follow-Up) - Non-Measurable Lymphoma Disease, Post-Treatment Response (Follow-Up) - Non-Measurable Lymphoma Disease, Post-Treatment Response (Follow-Up) - Response, Signature of Investigator

Study ID: 104512 Clinical Study ID: 104512 Study Title: Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody for Patients With Previously Treated Non Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992758 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Iodine-131 Anti-B1 Antibody Trade Name: Tositumomab Study Indication: Lymphoma, Non-Hodgkin

Oral Topotecan as Radiosensitizing Agent in Patients with Rectal Cancer; NCT00158886 - Topotecan Post-Study Minimal Follow-up Report

- 21/08/2019 - 1 Formulaire, 5 Groupes Item, 19 Eléments de données, 1 Langue

Groupes Item: Administrative documentation, Follow-Up Report, Month, Patient Outcome, Cessation of life, Investigator Signature

Study ID: 104864/517 Clinical Study ID: 104864/517 Study Title: A Phase I Study of Oral Topotecan as a Radiosensitizing Agent in Patients With Rectal Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158886 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Topotecan + Radiation therapy Trade Name: N/A Study Indication: Rectal Cancer, Carcinoma, Renal Cell

Oral Topotecan Daily x 5 Days vs. Oral Topotacan 5 Days On, 2 Days Off; 104864/502 - Post-Study Minimal Follow-Up Report

- 04/07/2019 - 1 Formulaire, 4 Groupes Item, 18 Eléments de données, 1 Langue

Groupes Item: Administrative documentation, Follow-Up Report, Month, Patient Outcome, Cessation of life

Study ID: 104864/502 Clinical Study ID: 104864/502 Study Title: An Open-Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second-Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: N/A Study Indication: Cancer, Locally Advanced or Metastatic Cervical Cancer

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Cancer and Non-Cancer related surgical Procedures; Investigational Product; Blood Products and Blood Supportive Care Products; Date of Visit/ Assessment; Unscheduled Lesion Assessment; Follow-Up; Follow-Up Anti-Cancer Therapy; Follow-Up Radiotherapy

- 29/05/2019 - 1 Formulaire, 9 Groupes Item, 54 Eléments de données, 1 Langue

Groupes Item: Prior Cancer and Non-Cancer related surgical procedures, Investigational Product, Investigational Product - Dose Modifications, Blood Products and Blood Supportive Care Products, Date of visit/ Assessment, Unscheduled Lesion Assessment, Follow-Up, Follow-Up Anti-Cancer Therapy, Follow-Up Anti-Cancer Radiotherapy

Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Patient Status GOAL Trial B-cell Lymphoma NCT02499003

- 31/12/2017 - 1 Formulaire, 4 Groupes Item, 11 Eléments de données, 1 Langue

Groupes Item: Administrative data, Patient status, patient alive, Patient deceased

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

CCR 2011 Template - Course Initiation

- 15/07/2017 - 1 Formulaire, 1 Groupe Item, 6 Eléments de données, 1 Langue

Groupe Item: Course Initiation

The course initiation Start Date, Arm, Treatment Assignment Code (TAC) and Treating Institution. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=ACFB66E7-BC95-6D16-E040-BB89AD4363C3

Mots-clés

Table des matières

Modèles de données sélectionnés